The Administrative Core is designed to provide overall leadership for the program project. The P.I., with the support of an administrative secretary, organizes and manages the different components of the program. This includes frequent interactions with the Co-P.l., Lead Investigators, and Core Leaders, internal program review and planning, organization of work-in-progress meetings, external review, scientific seminar series, and overall representation of the needs of the scientific and administrative programs. Core A communicates with the external and internal advisors, the Cancer Center Directors of the Wistar Institute, University of Pennsylvania, Memorial Sloan Kettering Cancer Center, and the NCI program staff. This Core serves the needs of the entire program on the etiology, progression and therapy of melanoma for the institutions on the Wistar/Penn and MSKCC campuses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA025874-32
Application #
8450873
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
32
Fiscal Year
2013
Total Cost
$115,727
Indirect Cost
$22,488
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Talevich, Eric; Shain, A Hunter; Botton, Thomas et al. (2016) CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Comput Biol 12:e1004873
Lu, Hezhe; Liu, Shujing; Zhang, Gao et al. (2016) Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep 15:2012-24
Krepler, Clemens; Xiao, Min; Samanta, Minu et al. (2016) Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. Oncotarget :
Shannan, Batool; Chen, Quan; Watters, Andrea et al. (2016) Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment Cell Melanoma Res 29:317-28
Krepler, Clemens; Xiao, Min; Sproesser, Katrin et al. (2016) Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res 22:1592-602
Yeh, Iwei; Tee, Meng Kian; Botton, Thomas et al. (2016) NTRK3 kinase fusions in Spitz tumours. J Pathol 240:282-290
Shannan, Batool; Perego, Michela; Somasundaram, Rajasekharan et al. (2016) Heterogeneity in Melanoma. Cancer Treat Res 167:1-15
Cierlitza, Monika; Chauvistré, Heike; Bogeski, Ivan et al. (2015) Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. Exp Dermatol 24:155-7
Qin, Jie; Rajaratnam, Rajathees; Feng, Li et al. (2015) Development of organometallic S6K1 inhibitors. J Med Chem 58:305-14
Carvajal, Richard D; Lawrence, Donald P; Weber, Jeffrey S et al. (2015) Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res 21:2289-96

Showing the most recent 10 out of 366 publications